Recombinant gelatins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8158756
APP PUB NO 20100119574A1
SERIAL NO

12527900

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
FUJIFILM MANUFACTURING EUROPE B.V.TILBURG54

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bouwstra, Jan Bastiaan Tilburg, NL 55 273
De, Boer Arjo Lysander Tilburg, NL 9 14
Van, Asten Peter Franciscus Theresius Maria Tilburg, NL 12 22
Van, Urk Hendrik Tilburg, NL 15 156

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
2003/0064,074 Recombinant gelatins in vaccines 39 2002
2005/0238,663 Recombinant stabilizer botulinum toxin pharmaceutical compositions 14 2004
2007/0190,153 Delivery systems for non-steroidal anti-inflammatory drugs (nsaids) 9 2004
2007/0196,496 Delivery systems for functional ingredients 12 2006
 
GEL-DEL TECHNOLOGIES, INC. (4)
2002/0028,243 Protein matrix materials, devices and methods of making and using thereof 218 2001
2003/0007,991 Devices including protein matrix materials and methods of making and using thereof 45 2001
2002/0106,410 Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices 14 2001
2005/0147,690 Biocompatible protein particles, particle devices and methods thereof 47 2004
 
MATRIX PHARMACEUTICAL, INC. (1)
5597578 TGF-.beta. protein compositions for inhibition of cell proliferation 38 1994
 
DEUTSCHE GELATINE-FABRIKEN STOESS AG (1)
5733994 Biodegradable, water-resistant polymer material 15 1996
 
CELLTRAN LIMITED (1)
6458386 Medicaments based on polymers composed of methacrylamide-modified gelatin 61 2000
 
KAKEN PHARMACEUTICAL CO., LTD. (1)
6831058 Crosslinked gelatin gel preparation containing basic fibroblast growth factor 22 1995
 
Ihara & Company Ltd. (1)
2006/0177,492 Collagen gel and process of producing the same 11 2005
 
INTELLIPHARMACEUTICS CORP. (1)
2006/0024,361 Disintegrant assisted controlled release technology 66 2004
 
SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (1)
4855134 Sustained-release preparation 28 1986
 
GEL-DEL TECHNOLOGIES (1)
6342250 Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices 62 1998
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
2006/0121,609 Gradient scaffolding and methods of producing the same 30 2005
 
FIBROGEN, INC. (4)
6992172 Recombinant gelatins 75 2000
2006/0147,501 Collagen compositions and biomaterials 26 2004
2005/0058,703 Gelatin capsules 8 2004
2009/0143,568 Recombinant gelatins 9 2008
 
BATTELLE MEMORIAL INSTITUTE (1)
2006/0024,346 Stabilization of biologically active proteins with mixtures of polysaccharides and amino acid based compounds 13 2004
 
FUJIFILM MANUFACTURING EUROPE B.V. (11)
6150081 Silver halide emulsions with recombinant collagen suitable for photographic application and also the preparation thereof 22 1998
2007/0004,034 Process for coating cell-culture support 9 2003
7517954 RGD-enriched gelatine-like proteins with enhanced cell binding 11 2004
2006/0241,032 Rgd-enriched gelatine-like proteins with enhanced cell binding 12 2004
2006/0204,511 Use of recombinant or synthetic gelatin as stabiliser in vaccines 5 2004
2007/0031,501 Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions 13 2004
2008/0107,666 Non-Glycosylated Recombinant Collagen-Like Polypeptides 7 2006
2008/0113,910 RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING 10 2007
2008/0114,078 RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING 10 2007
2008/0167,446 RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING 10 2007
2008/0274,957 RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING 10 2007
 
Alfatec-Pharma GmbH (1)
6068854 Sol-controlled thermocolloid matrix based on gelatin for oral sustained-release form 14 1996
 
2120812 ONTARIO INC. (2)
2004/0237,663 Delivery systems for functional ingredients 26 2003
2005/0208,141 Delivery systems for functional ingredients 15 2005
 
AMGEN INC. (2)
5399361 Collagen-containing sponges as drug delivery compositions for proteins 107 1994
5512301 Collagen-containing sponges as drug delivery compositions for proteins 57 1994
 
Medgel Corporation (1)
2006/0251,719 Sustained-release hydrogel preparation 12 2004
 
COVALON TECHNOLOGIES INC. (2)
2006/0068,013 Non-adhesive elastic gelatin matrices 19 2005
2007/0009,580 Non-adhesive hydrogels 8 2005
 
SPINE WAVE, INC. (1)
6140072 Functional recombinantly prepared synthetic protein polymer 40 1995
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (3)
5023082 Sustained-release pharmaceutical compositions 142 1988
5002769 Compositions for the sustained-release of chlorhexidine 30 1989
5897879 Sustained-release pharmaceutical system for the delivery of antioxidants 21 1997
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
FUJIFILM CORPORATION (2)
* 9597432 Cell construct comprising polymer blocks having biocompatibility and cells 0 2011
* 2012/0329,157 CELL CONSTRUCT COMPRISING POLYMER BLOCKS HAVING BIOCOMPATIBILITY AND CELLS 1 2011
 
FUJIFILM MANUFACTURING EUROPE B.V. (1)
9023619 Non-natural gelatin-like proteins with enhanced functionality 0 2011
 
HEART BIOTECH LIMITED (1)
* 2016/0194,378 PEPTIDES AND USES THEREOF 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 17, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 17, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00